Lee DH, Fusaro A, Song CS, Suarez DL, Swayne DE. Poultry vaccination directed evolution of H9N2 low pathogenicity avian influenza viruses in Korea. Virology. 2016;488:225–31.
Lau EH, Zhang SQ, Leung C, Cowling BJ, Wu JT, Peiris M. Identifying key transmission route of avian influenza A (H9N2) in live poultry markets. Online J Public Health Inform. 2017;9:e106.
Zhao YF, Diao FF, Yu JY, Zhang FX, Jiang CQ, Wang JL, Guo SY, Cui K, Liu CY, Wei XH, Jiang SJ, Xie ZJ. Intraspecies and interspecies transmission of mink H9N2 influenza virus. Sci Rep. 2017;7:7429.
Jaleel S, Younus M, Idrees A. Arshad M, khan AU, Ehtisham-ul-Haque S, Zaheer MI, Tanweer M, Towakal F, Munibullah, Tipu MY, Sohail ML, Umar S. pathological alterations in respiratory system during co-infection with low pathogenic avian influenza virus (H9N2) and Escherichia coli in broiler chickens. J Vet Res. 2017;61:253–8.
Arafat N, Eladl AH, Marghani BH, Saif MA, El-Shafei RA. Enhanced infection of avian influenza virus H9N2 with infectious laryngeotracheitis vaccination in chickens. Vet Microbiol. 2018;219:8–16.
Eladl AH, Alzayat AA, Ali HS, Fahmy HA, Ellakany HF. Comparative molecular characterization, pathogenicity and seroprevalence of avian influenza virus H9N2 in commercial and backyard poultry flocks. Comp Immunol Microbiol Infect Dis. 2019;64:81–9.
Matrosovich MN, Krauss S, Webster RG. H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity. Virology. 2001;281:156–62.
Lin YP, Shaw M, Gregory V, Cameron K, Lim W, Klimov A, Subbarao K, Guan Y, Krauss S, Shortridge K, Webster R, Cox N, Hay A. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci U S A. 2000;97:9654–8.
Butt KM, Smith GJ, Chen H, Zhang LJ, Leung YH, Xu KM, Lim W, Webster RG, Yuen KY, Peiris JS, Guan Y. Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol. 2005;43:5760–7.
Kim SH. Challenge for one health: co-circulation of zoonotic H5N1 and H9N2 avian influenza viruses in Egypt. Viruses. 2018;10:121.
Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Zhang Y, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368:1888–97.
Liu D, Shi W, Shi Y, Wang D, Xiao H, Li W, Bi Y, Wu Y, Li X, Yan J, Liu W, Zhao G, Yang W, Wang Y, Ma J, Shu Y, Lei F, Gao GF. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet. 2013;381:1926–32.
Sun YP, Liu JH. H9N2 influenza virus in China: a cause of concern. Protein Cell. 2015;6:18–25.
Luo CR, Zhao XN, Ning DM, Li D, Xu W. Discovery and response of the first case of human infection with avian influenza A (H9N2) virus in Yunnan Province, China. Chin J Zoonoses. 2017;33:241–4.
Huang YG, Jing ZC, Tong JW, Yu SS, Li GQ. 1 case of human infection with the investigation of H9N2 avian influenza disposal report in Mengzi city of Yunnan in 2016. J Med Pest Control. 2017;33:1085–7.
Kilany WH, Bazid AH, Ali A, El-Deeb AH, El-Abideen MA, Sayed ME, El-Kady MF. Comparative effectiveness of two oil adjuvant–inactivated avian influenza H9N2 vaccines. Avian Dis. 2016; 60 Suppl 1:226–31.
Shin JH, Mo JS, Kim JN, Mo I, Ha BD. Assessment of the safety and efficacy of low pathogenic avian influenza (H9N2) virus in inactivated oil emulsion vaccine in laying hens. J Vet Sci. 2016;17:27–34.
Ali ZM, Hassan MAEM, Hussein HA, Ahmed BM, El Sanousi AAE. Protective efficacy of combined trivalent inactivated ISA 71 oil adjuvant vaccine against avian influenza virus subtypes (H9N2 and H5N1) and Newcastle disease virus. Vet World. 2017;10:1212–20.
Lone NA, Spackman E, Kapczynski D. Immunologic evaluation of 10 different adjuvants for use in vaccines for chickens against highly pathogenic avian influenza virus. Vaccine. 2017;35:3401–8.
Riaz A, Shah MA, Hasan MU. Yameen M, Chaudhry M, Malik A, Zafar MA, Rehman SU, Gawri I. Comparative efficacy of different adjuvant containing inactivated vaccines against low-pathogenicity avian influenza H9N2 virus. Adv Life Sci. 2017;4:66–71.
Zhang AG, Lai HZ, Xu JH, Huang WK, Liu YF, Zhao DW, Chen RA. Evaluation of the protective efficacy of Poly I:C as an adjuvant for H9N2 subtype Avian influenza inactivated vaccine and its mechanism of action in ducks. PLoS One. 2017;12:e0170681.
Zhao J, Yang HM, Xu HJ, Ma ZB, Zhang GZ. Efficacy of an inactivated bivalent vaccine against the prevalent strains of Newcastle disease and H9N2 avian influenza. Virol J. 2017;14:56.
Bonam SR, Partidos CD, Skm H, Muller S. An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol Sci. 2017;38:771–93.
Sun HX, He SW, Shi MH. Adjuvant-active fraction from Albizzia julibrissin saponins improves immune responses by inducing cytokine and chemokine at the site of injection. Int Immunopharmacol. 2014;22:346–55.
Zhu BN, He TY, Gao XY, Shi MH, Sun HX. Evaluation and characteristics of immunological adjuvant activity of purified fraction of Albizia julibrissin saponins. Immunol Invest. 2019;48:283–302.
Sun YP, Pu J, Jiang ZL, Guan T, Xia YJ, Xu Q, Liu LQ, Ma B, Tian FL, Brown EG, Liu JH. Genotypic evolution and antigenic drift of H9N2 influenza viruses in China from 1994 to 2008. Vet Microbiol. 2010;146:215–25.
McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006;176:6333–9.
Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine. 2008;26:552–61.
Lee DH, Kwon JS, Lee HJ, Lee YN, Hur W, Hong YH, Lee JB, Park SY, Choi IS, Song CS. Inactivated H9N2 avian influenza virus vaccine with gel-primed and mineral oil-boosted regimen could produce improved immune response in broiler breeders. Poultry Sci. 2011;90:1020–2.
Li DY, Xue MY, Wang C, Wang JB, Chen PY. Bursopentine as a novel immunoadjuvant enhances both humoral and cell-mediated immune responses to inactivated H9N2 avian influenza virus in chickens. Clin Vaccine Immunol. 2011;18:1497–502.
Singh SM, Alkie TN, Hodgins DC, Nagy É, Shojadoost B, Sharif S. Systemic immune responses to an inactivated, whole H9N2 avian influenza virus vaccine using class B CpG oligonucleotides in chickens. Vaccine. 2015;33:3947–52.
Awadin WF, Eladl AH, El-Shafei RA, El-Adl MA, Ali HS. Immunological and pathological effects of vitamin E with Fetomune Plus® on chickens experimentally infected with avian influenza virus H9N2. Vet Microbiol. 2019;231:24–32.
Eladl AH, Arafat N, El-Shafei RA, Farag VM, Saleh RM, Awadin WF. Comparative immune response and pathogenicity of the H9N2 avian influenza virus after administration of Immulant®, based on Echinacea and Nigella sativa, in stressed chickens. Comp Immunol Microbiol Infect Dis. 2019;65:165-175.
Eladl AH, Mosad SM, El-Shafei RA, Saleh RM, Ali HS, Badawy BM, Elshal MF. Immunostimulant effect of a mixed herbal extract on infectious bursal disease virus (IBDV) vaccinated chickens in the context of a co-infection model of avian influenza virus H9N2 and IBDV. Comp Immunol Microbiol Infect Dis, 2020;72:101505.
Pedersen GK, Höschler K, Solbak SM, Bredholt G, Pathirana RD, Afsar A, Breakwell L, Nøstbakken JK, Raae AJ, Brokstad KA, Sjursen H,Zambon M, Cox RJ. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine. 2014;32:4550–7.
Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH, McCullers JA. Distinct contributions of vaccine- induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol. 2006;13:981–90.
Kreijtz JH, Bodewes R, van Amerongen G, Kuiken T, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine. 2007;25:612–20.
O’Neill E, Krauss SL, Riberdy JM, Webster RG, Woodland DL. Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol. 2001;81:2689–96.
Chakir H, Wang H, Lefebvre DE, Webb J, Scott FW. T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods. 2003;278:157–69.
He YF, Ni TT, Liu ZY, Ye YP, Sun HX. Rapid annotation and structural characterization of saponins in the active fraction of Albizia julibrissin by HPLC coupled with quadrupole time-of-flight mass spectrometry based on accurate mass database. J Sep Sci. 2019;42:2922–2941.
Xie Y, Sun HX, Li D. Platycodin D improves the immunogenicity of Newcastle disease virus-based recombinant avian influenza vaccine in mice. Chem Biodiv. 2010;7:677–89.
Sun HX, Wang H, Xu HS, Ni Y. Novel polysaccharide adjuvant from the roots of Actinidia eriantha with dual Th1 and Th2 potentiating activity. Vaccine.2009;27:3984–91.
Sun HX, Zhang J, Chen FY, Chen XF, Zhou ZH, Wang H. Activation of RAW264.7 macrophages by the polysaccharides from the roots of Actinidia eriantha and its Molecular mechanisms. Carbohyd Polym. 2015;121:388–402.
Du J, Chen XF, Wang CY, Sun HX. Pathway analysis of global gene expression change in dendritic cells induced by the polysaccharide from the roots of Actinidia eriantha. J Ethnopharmacol. 2018;214:141–52.